Kinetic solubility and dissolution velocity of rutin nanocrystals

European Journal of Pharmaceutical Sciences

Volumn 36, Issue 4-5, 2009, Pages 502-510

  Mauludin, Rachmat ^a   Müller, Rainer H ^a   Keck, Cornelia M ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Dissolution behavior; DSC; Kinetic solubility; Lyophilization; Nanocrystals; Nanosuspension; Rutin; X ray diffraction

Indexed keywords

BUFFER; DODECYL SULFATE SODIUM; NANOCRYSTAL; POLOXAMER; POLYSORBATE 80; POLYVINYL ALCOHOL; RUTOSIDE;

ARTICLE; CHEMICAL COMPOSITION; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; DRUG STRUCTURE; FREEZE DRYING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LASER DIFFRACTION; MICROSCOPY; NANOSUSPENSION; PARTICLE SIZE; PH; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SPRAY DRYING; SUSPENSION; X RAY POWDER DIFFRACTION;

CALORIMETRY, DIFFERENTIAL SCANNING; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRYSTALLOGRAPHY, X-RAY; FREEZE DRYING; KINETICS; NANOPARTICLES; RUTIN; SOLUBILITY;

EID: 59349119908     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2008.12.002     Document Type: Article

References (58)

1. Ahmed H., Buckton G., and Rawlins D.A. Crystallisation of partially amorphous griseofulvin in water vapour: determination of kinetic parameters using isothermal heat conduction microcalorimetry. Int. J. Pharm. 167 (1998) 139-145
2. Auweter, H., Bohn, H., Heger, R., Horn, D., Siegel, B., Siemensmeyer, K., 2002. Precipitated water-insoluble colorants in colloid disperse form. United States Patent 6,494,924.
3. Buckton G., and Beezer A.E. The relationship between particle size and solubility. Int. J. Pharm. 82 (1992) R7-R10
4. Calabro M.L., Tommasini S., Donato P., Stancanelli R., Raneri D., Catania S., Costa C., Villari V., Ficarra P., and Ficarra R. The rutin/beta-cyclodextrin interactions in fully aqueous solution: spectroscopic studies and biological assays. J. Pharm. Biomed. Anal. 36 (2005) 1019-1027
5. Chen S., Gong J., Liu F., and Mohammed U. Naturally occurring polyphenolic antioxidants modulate IgE-mediated mast cell activation. Immunology 100 (2000) 471-480
6. Day A.J., and Williamson G. Biomarkers for exposure to dietary flavonoids: a review of the current evidence for identification of quercetin glycosides in plasma. Br. J. Nutr. 86 Suppl 1 (2001) S105-S110
7. Deschner E.E., Ruperto J., Wong G., and Newmark H.L. Quercetin and rutin as inhibitors of azoxymethanol-induced colonic neoplasia. Carcinogenesis 12 (1991) 1193-1196
8. Dulfer W.J., Bakker M.W.C., and Govers H.A.J. Micellar solubility and micelle/water partitioning of polychlorinated biphenyls in solutions of sodium dodecyl sulfate. Environ. Sci. Technol. 29 (1995) 985-992
9. Graefe E.U., Wittig J., Mueller S., Riethling A.K., Uehleke B., Drewelow B., Pforte H., Jacobasch G., Derendorf H., and Veit M. Pharmacokinetics and bioavailability of quercetin glycosides in humans. J. Clin. Pharmacol. 41 (2001) 492-499
10. Haiyun D., Jianbin C., Guomei Z., Shaomin S., and Jinhao P. Preparation and spectral investigation on inclusion complex of beta-cyclodextrin with rutin. Spectrochim. Acta A: Mol. Biomol. Spectrosc. 59 (2003) 3421-3429
11. Hecq J., Deleers M., Fanara D., Vranckx H., and Amighi K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int. J. Pharm. 299 (2005) 167-177
12. Hu J., Johnston K.P., and Williams R.O. Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug Dev. Ind. Pharm. 30 (2004) 233-245
13. Ihme N., Kiesewetter H., Jung F., Hoffmann K.H., Birk A., Muller A., and Grutzner K.I. Leg oedema protection from a buckwheat herb tea in patients with chronic venous insufficiency: a single-centre, randomised, double-blind, placebo-controlled clinical trial. Eur. J. Clin. Pharmacol. 50 (1996) 443-447
14. Jinno J., Kamada N., Miyake M., Yamada K., Mukai T., Odomi M., Toguchi H., Liversidge G.G., Higaki K., and Kimura T. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J. Control Release 111 (2006) 56-64
15. Jouyban A. In silico prediction of drug solubility in water-dioxane mixtures using the Jouyban-Acree model. Pharmazie 62 (2007) 46-50
16. Kanaze F.I., Kokkalou E., Niopas I., Georgarakis M., Stergiou A., and Bikiaris D. Dissolution enhancement of flavonoids by solid dispersion in PVP and PEG matrixes: a comparative study. J. Appl. Polym. Sci. 102 (2006) 460-471
17. Kipp, J. E., Wong, J. C. T., Doty, M. J., Rebbeck, C. L., 2003. Microprecipitation method for preparing submicron suspensions. United States Patent 6,607,784.
18. Kipp, J. E., Wong, J. C. T., Doty, M. J., Werling, J., Rebbeck, C. L., Brynjelsen, S., 2005. Method for preparing submicron particle suspensions. United States Patent 6,884,436.
19. Letellier P., Mayaffre A., and Turmine M. Solubility of nanoparticles: nonextensive thermodynamics approach. J. Phys.: Condens. Matter 19 (2007) 436229-436238
20. Li Y.P., Zhang X.Y., Zhou J.J., and Pei Y.Y. Preparation and dissolution property of ipriflavone solid dispersion. Zhongguo Yao Li Xue Bao 20 (1999) 957-960
21. Lipinski C.A. Avoiding investment in doomed drugs, is poor solubility an industry wide problem?. Curr. Drug Dis. 1 (2001) 17-19
22. Lipinski C.A. Poor aqueous solubility-an industry wide problem in drug discovery. Am. Pharm. Rev. 5 (2002) 82-85
23. List, M., Sucker, H., 1988. Pharmaceutical colloidal hydrosols for injection. GB Patent 2,200,048.
24. Liversidge G.G., and Conzentino P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm. 125 (1995) 309-313
25. Liversidge G.G., and Cundy K.C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int. J. Pharm. 125 (1995) 91-97
26. Liversidge, G.G., Cundy, K.C., Bishop, J. F., Czekai, D. A., 1992. Surface modified drug nanoparticles. United States Patent 5,145,684.
27. Liversidge, G. G., Phillips, C. P., Cundy, K. C., 1994. Method to reduce particle size growth during lyophilization. United States Patent 5,302,401.
28. Loftsson T., Brewster M., and Másson M. Role of Cyclodextrins in Improving Oral Drug Delivery. Am. J. Drug. Deliv. 2 (2004) 261-275
29. Loftsson T., and Brewster M.E. Pharmaceutical applications of cyclodextrins 1. Drug solubilization and stabilization. J. Pharm. Sci. 85 (1996) 1017-1025
30. Manach C., Morand C., Crespy V., Demigné C., Texier O., Régérat F., and Rémésy C. Quercetin is recovered in human plasma as conjugated derivatives which retain antioxidant properties. FEBS Lett. 426 (1998) 331-336
31. Middleton E., Kandaswami C., and Theoharides T.C. The effects of plant flavonoids on mammalian cells:implications for inflammation, heart disease, and cancer. Pharm. Rev. 52 (2000) 673-751
32. Müller R.H., and Akkar A. Drug nanocrystals of poorly soluble drugs. In: Nalwa H.S. (Ed). Encyclopedia of Nanoscience and Nanotechnology. (2004), American Scientific Publishers 627-638
33. Müller, R. H., Becker, R., Kruss, B., Peters, K., 1999. Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution. United States Patent 5,858,410.
34. Müller R.H., Benita S., and Böhm B. Emulsions and nanosuspensions for the formulation of poorly soluble drugs. Medpharm. Stuttgart (1998)
35. Müller R.H., Jacobs C., and Kayser O. Nanosuspensions for the formulation of poorly soluble drugs. In: Nielloud F., and Marti-Mestres G. (Eds). Pharmaceutical Emulsions and Suspensions. (2000), Marcel Dekker 383-407
36. Müller R.H., Jacobs C., and Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47 (2001) 3-19
37. Müller R.H., Jacobs C., and Kayser O. DissoCubes - a novel formulation for poorly soluble and poorly bioavailable drugs. In: Rathbone M.J., Hadgraft J., and Roberts M.S. (Eds). Modified-Release Drug Delivery Systems (2003), Marcel Dekker 135-149
38. Müller R.H., and Keck C.M. Improvement of Delivery & Solubility of Poorly Soluble Drugs by Nanonisation. (2007), LTS Academy, Petersberg pp.12-17
39. Müller, R. H., Mäder, K., Krause, K., 2000b. Verfahren zur schonenden Herstellung von hochfeinen Micro-/Nanopartikeln. PCT Application PCT/EP00/06535.
40. Müller R.H., Peters K., Becker R., and Kruss B. Nanosuspensions for the i.v. administration of poorly soluble drugs-stability during sterilization and long-term storage (1995), 22 nd International Symposium of Controlled Release of Bioactive Materials, Washington DC 574-575
41. Noyes A.A., and Whitney W.R. The rate of solution of solid substances in their own solutions. J. Am. Chem. Soc. 19 (1897) 930-934
42. O'Neil, M. J., 2006. The Merck index: An Encyclopedia of Chemicals, Drugs, and Biologicals, 14th Edition. Merck.
43. Ohta M., Oguch T., and Yamamoto K. Evaluation of solubility parameter to predict apparent solubility of amorphous and crystalline cefditoren pivoxil. Pharm. Acta Helv. 74 (1999) 59-64
44. Panasiak W., Wleklik M., Oraczewska A., and Luczak M. Influence of flavonoids on combined experimental infections with EMC virus and Staphylococcus aureus in mice. Acta Microbiol. Pol. 38 (1989) 185-188
45. Pikal M.J., Lukes A.L., Lang J.E., and Gaines K. Quantitative crystallinity determinations for beta-lactam antibiotics by solution calorimetry: correlations with stability. J. Pharm. Sci. 67 (1978) 767-773
46. Radtke M. Nanopure™ pure drug nanoparticles for the formulation of porly soluble drugs. NewDrugs 3 (2001) 62-68
47. Rao M.Y., Kumar M., and Apte S. Formulation of nanosuspensions of albendazole for oral administration. Curr. Nanosci. 4 (2008) 53-58
48. Stegemann S., Leveiller F., Franchi D., de Jong H., and Linden H. When poor solubility becomes an issue: from early stage to proof of concept. Eur. J. Pharm. Sci. 31 (2007) 249-261
49. Stovall D.M., Givens C., Keown S., Hoover K.R., Barnes R., Harris C., Lozano J., Nguyen M., Rodriguez E., Acree J.W.E., and Abraham M.H. Solubility of crystalline nonelectrolyte solutes in organic solvents: mathematical correlation of 4-chloro-3-nitrobenzoic acid and 2-chloro-5-nitrobenzoic acid solubilities with the Abraham solvation parameter model. Phys. Chem. Liq. 43 (2005) 351-360
50. Sucker, H., Gassmann, P., 1994. Improvements in pharmaceutical compositions. European Patent 0,580,690.
51. Taha I.K., Favid J.M., and Mahmoud M.A. Rutin. In: Florey K. (Ed). Analytical Profiles of Drug Substances (1983), Academic Press Inc., London 623-681
52. TCI, 2007. Strategies for bioavailability enhancement of poorly soluble or poorly permeable drugs. Technology Catalysts International (TCI), Falls Church.
53. Tom J.W., and Debenedetti P.G. Particle formation with supercritical fluids-a review. J. Aerosol. Sci. 22 (1991) 555-584
54. Wang Z., Deng Y., Sun S., and Zhang X. Preparation of hydrophobic drugs cyclodextrin complex by lyophilization monophase solution. Drug. Dev. Ind. Pharm. 32 (2006) 73-83
55. Wenju W., and Nancollas G.H. A new understanding of the relationship between solubility and particle size. J. Solution Chem. 27 (1998) 521-531
56. Wu T.H., Yen F.L., Lin L.T., Tsai T.R., Lin C.C., and Cham T.M. Preparation, physicochemical characterization, and antioxidant effects of quercetin nanoparticles. Int. J. Pharm. 346 (2008) 160-168
57. Yonemochi E., Kitahara S., Maeda S., Yamamura S., Oguchi T., and Yamamoto K. Physicochemical properties of amorphous clarithromycin obtained by grinding and spray drying. Eur. J. Pharm. Sci. 7 (1999) 331-338
58. Young T.J., Mawson S., Johnston K.P., Henriksen I.B., Pace G.W., and Mishra A.K. Rapid expansion from supercritical to aqueous solution to produce submicron suspensions of water-insoluble drugs. Biotechnol. Prog. 16 (2000) 402-407